reason report
sale growth momentum pois continu
bottom line share trade today compani deliv
anoth solid quarter -- organ top-lin growth admittedli
easier comp though still strongest sale growth quarter recent
memori -- fundament remain strong new product growth
momentum continu build manag rais sale guidanc
previous indic organ
growth back half year us suggest growth
momentum sustain view print encourag
number potenti driver above-market growth outlook
ramp adopt freestyl libr expect instal
base reach total -- intern --
end today respect
estim instal base
ou end solid uptick nutrit
consecut quarter growth acceler sale growth solidli
mid-single-digit rang least suggest busi
could sustain healthi low- mid-single-digit growth go forward
growth slow area includ neuromodul
cardiac rhythm manag note much
company-specif tie primarili too-slow sale forc build neuro
replac headwind tough compar us
much execut stori compani integr two recent
major acquisit stj alr drive new product cycl
medic devic busi steadi turnaround
nutrit busi quarter perform seem
posit datapoint support view success
execut valuat rel now-high expect
keep us sidelin acknowledg fundament
seem improv
reiter mp pt believ build sustain growth
momentum acceler growth trajectori compel
view believ share near full valuat
deliv estim upsid even better execut behind recent
upcom new product launch believ share could
appreci price target assum stabl multipl
ep appli higher ep estim
organ report mainli
reflect neg fx impact estim
basic unchang vs expect
growth momentum sustain addit track
pay debt -- increment year -- like exit
flexibl balanc sheet like shift capit
deploy prioriti toward dividend
compani inform leerink partner llc research
revenu mm ep includ stock compens expens exclud amort
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep estim
pleas refer page import disclosur price chart analyst certif
rate share market perform price target abbott like
path top-lin growth acceler compani like reinvest
busi absorb acquisit includ alr stj deal
potenti bolster compani sale ep growth outlook becom
formid player med-tech diagnost even broader offer
near term uncertainti around integr stj alr like continu
reflect market sentiment beyond believ margin expans continu
remain key piec abbott long-term invest thesi abbott also attract investor
look safer defens stock healthi dividend yield current
increasingli volatil market help sustain current multipl abbott
succeed drive meaning margin expans nutrit busi margin
mid-teen level post-split still go increas cost effici
suppli chain manufactur abbott pipelin also number smaller
increment new product launch expect next year beyond
pend acquisit xienc stori larg play estim basic
stabl drug elut stent market share next year view abbott like
less acquisit immedi term two larg acquisit underway alreadi
estim reflect uncertainti around integr larg acquisit stj
expect share trade assum multipl ep
estim assum share sustain current price-to-earnings multipl
ep estim clearli pois sale growth acceler next year believ
current valuat alreadi reflect potenti execut risk around new product
launch -- heavili depend notabl freestyl libr mri-saf high power
devic -- see opportun potenti downsid vs meaning clear-cut upsid
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
cardiovascular neuromodul
cardiovascular neuromodul intern
total cardiovascular neuromodul
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
cardiovascular neuromodul domest
cardiovascular neuromodul intern
total cardiovascular neuromodul
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
sg sale
 sale
diagnost contribut
neg fx impact
around
sale
use sale baselin
organ growth rapid diagnost
contribut littl posit fx
impact full year
somewhat
adjust
gain exchang
net interest expens
adjust ep
y/i mid-point
diagnost contribut posit
organ sale growth
fx impact
around
somewhat
sale
use sale baselin
organ growth rapid diagnost
somewhat
contribut posit fx impact littl
adjust
organ sale growth
baselin rapid diagnost
somewhat
contribut littl posit
adjust
fx impact
use sale baselin
organ growth rapid diagnost
somewhat
contribut posit fx impact littl
adjust
gain exchang
net interest expens
adjust ep
y/i mid-point
gain exchang
net interest expens
adjust ep
y/i mid-point
mid high-single-digit ex fx
mid high-single-digit
improv sale
growth around
mid high-singl digit
fx double-digit growth
diabet sever
double-digit growth
mid- high singl
failur
singl digit declin
rhythm manag
mid-singl digit ex fx
mid-singl digit ex fx
mid-singl digit
mid-singl digit ex
assess mitraclip
percutan therapi heart
purpos coapt trial confirm safeti effect
mitraclip system treatment moderate-to-sever sever function mitral
regurgit fmr symptomat heart failur subject treat per
standard care determin site local heart team
appropri mitral valv surgeri random control trial provid
opportun strengthen add label claim regard safeti clinic
benefit mitraclip system symptomat heart failur patient
moderate-to-sever sever function mitral regurgit
object studi evalu safeti effect
lva demonstr non-inferior hmii lva hmii use
treatment advanc refractori left ventricular heart failur
lva intend provid hemodynam support patient
advanc refractori left ventricular heart failur either short term support
bridg cardiac transplant btt myocardi recoveri long term
support destin therapi dt intend use insid
outsid hospit
approxim subject random investig site
approxim subject target receiv studi devic
final data collect date primari outcom measur juli
fda approv
